The depot injection is restricted to Consultant Paediatricians for the treatment of infantile spasams.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

The government has introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland.

The emergency ban will last from 3 June to 3 September 2024. It will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland.

During this period no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or incongruence under the care of these prescribers. Additional measures may be put in place following the General Election.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

This is Red in the Black Country IMOC formulary. i.e. for hospital prescribing only.

This is commssioned by NHSE for the indications below and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

Acomegaly in children as third-line treatment

All somatropin products are AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

Where availabe a Blueteq form will have to be completed for each patient.

This is commssioned by NHSE for the indications below and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

Treatment of Cushing's disease

Consultant diabetologists, and GPs with a special interest.

Consultant diabetologists, and GPs with a special interest.

This is AI in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initiation.

Some of the proucts are AI in the black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initiation. Please see individual products for details.

Metformin should be prescribed generically.

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

This is commissioned by the ICB for obesity and a Blueteq form must be completed before prescribing, but please note, BSol patients do not require a Blueteq form. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

Wegovy is Red in the Black Country IMOC formulary and is restricted to prescribing by commissioned clinics in secondary care by a consultant led specialist multidisciplinary Tier 3 weight management service with a commercial agreement in place. Prescribe by brand on a hospital outpatient form ONLY to avoid patients inadvertently receiving a different product licensed for type 2 diabetes and to ensure that hospital discount is obtained. Do not prescribe using FP10s.

Ozempic and Rybelsus should be prescribed ONLY for type 2 diabetes. 

Sitagliptin should be prescribed generically.

For obesity only for patients treated by the weight management clinic who meet the NICE criteria.

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

Diabetic nephropathy and only when prescribed generically

Qutenza is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

Please prescribe by brand.

Diprosone is AR in the Black Country IMOG formulary, i.e. it may be prescribed in primary care after a specialist recommendation.

Intravitreal treatment by consultant ophthalmologists in accordance with the NICE guidelines and criteria. This is Red in the Black Country formulary.

This is commissioned by NHSE for non-infectious uveitis in post-pubescent children and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

All other ophthalmological indications for the implant are ICB commissioned and a Blueteq form should be completed, if available.

Hydrocortisone in inflammatory bowel disease is AR in the Black Country formulary.

Hydrocortisone should be prescribed generically.

Tablets are restricted for the treatment of relapsing multiple sclerosis only.

The Black Country IMOC formulary status of methylprednisolone products is dependent on the indication: For endocrine indications the status is Black for musculoskeletal and neurology indications products will be in the formulary.

The Black Country IMOC formulary status of triamcinolone products is dependent on the indication: For endocrine indications the status is Black for musculoskeletal and neurology indications products will be in the formulary.

This oral form is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only and for specialist use. 

Consultant endocrinologists only.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

This is commssioned by NHSE for the indications below and a Blueteq form must be completed before prescribing. Please contact the Pharmacy High-Cost Drugs team if any assistance is required.

Treatment of Cushing's disease

Second-line

Oral formulations are second line to patches 

Oncological treatment only by those experienced in its use.

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

This is AI for the gel, i.e. can be prescribed in primary care after specialist initiation, but only for male hypogonadism or testosterone replacement in males.

This is AR in the Black Country IMOC formulary, i.e. it can be prescribed in primary care after specialist recommendation but only for male hypogonadism or testosterone replacement in males.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

Suppression of lactation only.

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

Consultant gynaecologists and endocrinology, (it is also allowed for Neurologists and Parkinson's disease second-line noting MHRA guidance - see chapter 4).

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

This is AI in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initaition.

For third-line use after oral bisphosphonates, IV bisphosphonates or denosumab

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

For endocrine uses calcitriol is second-line after alfacalcidol.

This is AI in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initiation.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only. a biosimilar product, Ponlimsi, will be rolled out i nthe Trust from February 2026.

Blueteq is reuired for the osteroporosis indication which is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specilaist recommendation. An ESCA or RICaD is in development. Please contact the Pharmacy High Cost Drug team if any support needed.

https://www.blueteq-secure.co.uk/Trust/default.aspx

There is no Blueteq form for the Xgeva brand.

N.B. the MHRA's Drug Safety Update in February 2013

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

This is Red for bone metabolism disorders in the Black Country IMOC formulary, i.e. for hospital prescribing only.

Second line after alendronic acid. Prescribe generically

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

This is AI in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initiation.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

If available a Blueteq form will have to be completed for each patient.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

MRC myeloma trial, use in metastatic prostate cancer and myeloma, and by Consultant Rheumatologists for patients unable to take oral bisphosphonates.

Only the generic product is stocked. All prescriptions for Aclasta® will be switched to the generic product.

This is AR for paediatric nocturnal enuresis and diabetes insipdus in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

Risk of severe harm or death when desmopressin is omitted or delayed in patients with cranial diabetes insipidus

ITU, Gastroenterology, and Consultant Gynaecologists in myomectomy

Vasopressin is not avaible, we stock argipressin (synthetic vasopressin).

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only in cases of hyponatraemia due to SIADH. It is Black for antimicrobial use.

Check indication before prescribing and specify the brand and indication on the prescription.

A Blueteq form will have to be completed for treating autosomal dominant polycystic kidney disease.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

Prescribers should note the the SPC for Jinarc® suggests

To mitigate the risk of significant and/or irreversible liver injury, blood testing for hepatic transaminases and bilirubin is required prior to initiation of Jinarc, continuing monthly for 18 months and at regular 3-monthly intervals thereafter.

and

During the first 18 months of treatment, Jinarc can only be supplied to patients whose physician has determined that liver function supports continued therapy.

See other cautions below.

This is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only.

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.

This is AI in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initiation.

Only the generic tablets are formulary. All branded products, capsule and the oral liquid are non-formulary

The capsules are AI in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initiation. Not all products are formulary. The injection is Red, i.e. for hospital prescribing only.

The government has introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland.

The emergency ban will last from 3 June to 3 September 2024. It will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland.

During this period no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or incongruence under the care of these prescribers. Additional measures may be put in place following the General Election.

The government has introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland.

The emergency ban will last from 3 June to 3 September 2024. It will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland.

During this period no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or incongruence under the care of these prescribers. Additional measures may be put in place following the General Election.

3.6 mg - for breast cancer
10.8 mg - for use at prostate clinic only (second-line use). Leuprorelin is the first-line product.

This is AI in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initaition.

The government has introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland.

The emergency ban will last from 3 June to 3 September 2024. It will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland.

During this period no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or incongruence under the care of these prescribers. Additional measures may be put in place following the General Election.

The government has introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland.

The emergency ban will last from 3 June to 3 September 2024. It will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland.

During this period no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or incongruence under the care of these prescribers. Additional measures may be put in place following the General Election.

For oncological treatment of those experienced, and for first-line use in Gynaecology/Urology. The 11.25g product is formulary for the licensed indication only.

This is AI in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist initaition.

The government has introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland.

The emergency ban will last from 3 June to 3 September 2024. It will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland.

During this period no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or incongruence under the care of these prescribers. Additional measures may be put in place following the General Election.

For patients who fit the pathway.

The government has introduced regulations to restrict the prescribing and supply of puberty-suppressing hormones, known as ‘puberty blockers’, to children and young people under 18 in England, Wales and Scotland.

The emergency ban will last from 3 June to 3 September 2024. It will apply to prescriptions written by UK private prescribers and prescribers registered in the European Economic Area (EEA) or Switzerland.

During this period no new patients under 18 will be prescribed these medicines for the purposes of puberty suppression in those experiencing gender dysphoria or incongruence under the care of these prescribers. Additional measures may be put in place following the General Election.

Salvactyl is Red in the Black Country IMOC formulary, i.e. for hospital prescribing only. Decapteptyl SR for endometriosis is AI in the IMOC formulary, i.e. may be prescribed in primary care after specialist inititation. Gonapeptyl Depot is Black.

For oncological treatment, or for immunological therapy by those experienced.

This is AR in the Black Country IMOC formulary, i.e. may be prescribed in primary care after specialist recommendation.